Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists

a technology of cyclohexyl acids and triazole, which is applied in the field of substituted triazole compounds, can solve problems such as end-organ failur

Active Publication Date: 2019-06-20
BRISTOL MYERS SQUIBB CO
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides compounds, pharmaceutical compositions, and medicaments that target LPA receptors, specifically LPA1. These compounds offer a means to develop new treatments for diseases that have been linked to these receptors.

Problems solved by technology

Fibrosis is the result of an uncontrolled tissue healing process leading to excessive accumulation and insufficient resorption of extracellular matrix (ECM) which ultimately results in end-organ failure (Rockey, D. C., et al., New Engl. J. Med., 2015, 372, 1138-1149).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
  • Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
  • Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0522]To a solution of Example 1H (8 mg, 0.021 mmol) and (S)-2-methylbutyl (4-nitrophenyl) carbonate (7 mg, 0.027 mmol) in THF (0.4 mL) was added N-ethyl-N-isopropylpropan-2-amine (11 μL, 0.062 mmol). The mixture was stirred at RT for 1 h, after which THF (0.8 mL) / H2O (0.4 mL) / MeOH (0.4 mL) and LiOH.H2O (5 mg, 0.105 mmol) were added. The reaction mixture was stirred at RT overnight, then was concentrated in vacuo and diluted with H2O (5 mL). The pH of the mixture was adjusted with 1N aq. HCl to ˜5 and extracted with EtOAc (3×5 mL). The combined organic extracts were washed with brine (2 mL), dried (MgSO4) and concentrated in vacuo. The residual crude product was purified by preparative LC / MS. Column: Waters XBridge C18, 19×200 mm, 5-μm particles; Guard Column: Waters XBridge C18, 19×10 mm, 5-m particles; Mobile Phase A: 5:95 MeCN:H2O with 0.1% TFA; Mobile Phase B: 95:5 MeCN:H2O with 0.1% TFA; Gradient: 50-90% B over 20 min, then a 5 min hold at 100% B; Flow: 20 mL / min. Fractions con...

example 2

(1 S,3S)-3-((2-Methyl-6-(1-methyl-5-((methyl(((S)-2-methylbutoxy)carbonyl)amino) methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexanecarboxylic acid

[0523]

[0524]To a 0° C. mixture of Example 1 compound (1.7 mg, 3.70 μmol) in DMF (0.2 mL) under N2 was added NaH (0.5 mg of a 60% dispersion in mineral oil; 0.011 mmol) and the reaction was stirred for 30 min at 0° C. MeI (0.7 μL, 0.011 mmol) was then added and the reaction was stirred at RT for 1 h, then was concentrated in vacuo. The residue was dissolved in THF (0.8 mL) / MeOH (0.4 mL) / water (0.4 mL) and LiOH.H2O (1 mg, 18.5 μmol) was added at RT. The reaction mixture was stirred at RT overnight, then was concentrated in vacuo and diluted with H2O (5 mL). The pH of the mixture was adjusted with 1N aq. HCl to ˜5 and the mixture was extracted with EtOAc (3×5 mL). The combined organic extracts were washed with brine (2 mL), dried (MgSO4) and concentrated in vacuo. This crude product was purified by preparative LC / MS: Column: Waters XB...

example 3

[0528]To a solution of crude Example 3A (12.7 mg, 0.026 mmol) in THF (0.8 mL) / H2O (0.400 mL) / MeOH (0.400 mL) was added LiOH.H2O (6 mg, 0.13 mmol) at RT. The mixture was stirred at RT overnight, then was concentrated in vacuo; the residue was diluted with H2O (5 mL), and the pH was adjusted with 1N aq. HCl to ˜5. The mixture was extracted with EtOAc (3×5 mL). The combined organic extracts were washed with brine (2 mL), dried (MgSO4) and concentrated in vacuo. The crude product was purified by preparative HPLC (Phenomenex Luna Axia 5μ C18 30×100 mm; 10 min gradient from 85% A: 15% B to 0% A: 100% B (A=90% H2O / 10% ACN+0.1% TFA); (B=90% ACN / 10% H2O+0.1% TFA); detection at 220 nm) to give the title compound (11.3 mg, 0.025 mmol, 98% yield). −1H NMR (500 MHz, CDCl3) δ 8.14 (d, J=8.8 Hz, 1H), 7.92 (d, J=9.1 Hz, 1H), 4.90-4.81 (m, 1H), 4.59 (s, 2H), 4.20 (s, 3H), 4.08 (t, J=6.6 Hz, 2H), 2.95-2.83 (m, 1H), 2.75 (s, 3H), 2.23-2.13 (m, 1H), 2.03-1.76 (m, 6H), 1.73-1.55 (m, 3H), 1.42-1.31 (m, 2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides compounds of Formula (I):or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the priority benefit of U.S. Provisional Application No. 62 / 607,399, filed Dec. 19, 2017; the entire content of which is herein incorporated by reference.FIELD OF THE INVENTION[0002]The present invention relates to novel substituted triazole compounds, compositions containing them, and methods of using them, for example, for the treatment of disorders associated with one or more of the lysophosphatidic acid (LPA) receptors.BACKGROUND OF THE INVENTION[0003]Lysophospholipids are membrane-derived bioactive lipid mediators, of which one of the most medically important is lysophosphatidic acid (LPA). LPA is not a single molecular entity but a collection of endogenous structural variants with fatty acids of varied lengths and degrees of saturation (Fujiwara et al., J Biol. Chem., 2005, 280, 35038-35050). The structural backbone of the LPAs is derived from glycerol-based phospholipids such as phosphatidylcholine (PC) or p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D401/04C07D403/04C07D249/06
CPCC07D401/04A61P11/00C07D249/06C07D403/04A61P37/06A61P35/00A61P19/10A61P29/00A61P1/16A61P13/12A61P3/10A61P9/10A61P35/02A61P27/02A61P9/00A61P25/04A61P17/00A61P35/04A61P11/06A61P1/00C07C249/06C07C403/04A61K31/4439A61K31/496A61P43/00
Inventor SHI, YANCHENG, PETER TAI WAHWANG, YINGSHI, JUNTAO, SHIWEILI, JUNKENNEDY, LAWRENCE J.KALTENBACH, III, ROBERT F.ZHANG, HAOCORTE, JAMES R.
Owner BRISTOL MYERS SQUIBB CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com